Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2013

Open Access 01-12-2013 | Review

Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy

Authors: Madhav Desai, Kate J Newberry, Jorge Romaguera, Liang Zhang, Zhishuo Ou, Michael Wang

Published in: Journal of Hematology & Oncology | Issue 1/2013

Login to get access

Abstract

Lenalidomide is an immunomodulatory agent which has been approved for multiple myeloma. Lenalidomide is also effective in and tolerated well by patients with follicular lymphoma, diffuse large B-cell lymphoma, and transformed large cell lymphoma. This review summarizes the results of current preclinical and clinical studies of lenalidomide, alone or in combination with the monoclonal antibody rituximab, as a therapeutic option for these three lymphoma types. This review will serve as a tool guiding future clinical investigations to improve survival rates for these three lymphomas.
Appendix
Available only for authorised users
Literature
1.
Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999, 341 (21): 1565-1571. 10.1056/NEJM199911183412102.CrossRefPubMed
2.
Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR: Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006, 24 (3): 431-436. 10.1200/JCO.2005.03.0221.CrossRefPubMed
3.
Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM: Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006, 24 (27): 4507-4514. 10.1200/JCO.2006.05.6689.CrossRefPubMed
4.
Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, Rossi D, Gentilini F, Crippa C, Galli M: Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011, 29 (8): 986-993. 10.1200/JCO.2010.31.6844.CrossRefPubMed
5.
6.
Bartlett JB, Dredge K, Dalgleish AG: The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004, 4 (4): 314-322. 10.1038/nrc1323.CrossRefPubMed
7.
Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D: Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008, 26 (30): 4952-4957. 10.1200/JCO.2007.15.3429.CrossRefPubMed
8.
Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, Bouabdallah R, Haioun C, Tilly H, Guo P: An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011, 22 (7): 1622-1627. 10.1093/annonc/mdq626.CrossRefPubMed
9.
Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Pietronigro D, Takeshita K: Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol. 2009, 27 (32): 5404-5409. 10.1200/JCO.2008.21.1169.CrossRefPubMed
10.
Chanan-Khan AA, Cheson BD: Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol. 2008, 26 (9): 1544-1552. 10.1200/JCO.2007.14.5367.CrossRefPubMed
11.
Gandhi AK, Kang J, Naziruddin S, Parton A, Schafer PH, Stirling DI: Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res. 2006, 30 (7): 849-858. 10.1016/j.leukres.2006.01.010.CrossRefPubMed
12.
Zhu D, Corral LG, Fleming YW, Stein B: Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother. 2008, 57 (12): 1849-1859. 10.1007/s00262-008-0512-7.CrossRefPubMed
13.
Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB: lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008, 14 (14): 4650-4657. 10.1158/1078-0432.CCR-07-4405.CrossRefPubMed
14.
Reddy NM, Hernandez-Ilizaliturri FJ, Czuczman MS: he use of the immunomodulatory drug, lenalidomide (Revlimid(R)) as a novel strategy to overcome acquired antibody resistance in rituximab-resistant non-Hodgkin's lymphoma (NHL) cell lines. AACR Meeting Abstracts. 2006, 2006 (1): 154-a-
15.
Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC: Thalidomide and lenalidomide: mechanism-based potential drug combinations. Leuk Lymphoma. 2008, 49 (7): 1238-1245. 10.1080/10428190802005191.CrossRefPubMed
16.
Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, Shirley MA, Muller G, Schafer P, Stirling D: Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res. 2005, 69 (1–2): 56-63.CrossRefPubMed
17.
Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, Macdougall F, Lister TA, Lee AM, Calaminici M, Gribben JG: Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood. 2009, 114 (21): 4713-4720. 10.1182/blood-2009-04-217687.PubMedCentralCrossRefPubMed
18.
Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H: Identification of a primary target of thalidomide teratogenicity. Science. 2010, 327 (5971): 1345-1350. 10.1126/science.1177319.CrossRefPubMed
19.
Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL: Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011, 118 (18): 4771-4779. 10.1182/blood-2011-05-356063.PubMedCentralCrossRefPubMed
20.
Plosker GL, Figgitt DP: Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003, 63 (8): 803-843. 10.2165/00003495-200363080-00005.CrossRefPubMed
21.
Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB, Yi Q, Wang M: Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol. 2009, 84 (9): 553-559. 10.1002/ajh.21468.CrossRefPubMed
22.
Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS: Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005, 11 (16): 5984-5992. 10.1158/1078-0432.CCR-05-0577.CrossRefPubMed
23.
Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, Wallace P, Czuczman MS: Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2008, 140 (1): 36-45.PubMed
24.
Richardson SJ, Eve HE, Copplestone JA, Dyer MJ, Rule SAJ: Activity of thalidomide and lenalidomide in mantle cell lymphoma. Acta Haematol. 2010, 123 (1): 21-29. 10.1159/000257990.CrossRefPubMed
25.
Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadie M, Spinelli JJ: Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007, 110 (2): 695-708. 10.1182/blood-2006-11-051672.PubMedCentralCrossRefPubMed
26.
Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H: SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations). 1975, Bethesda: National Cancer Institute, MD, http://​seer.​cancer.​gov/​csr/​1975_​2009_​pops09/​, based on November 2011 SEER data submission, posted to the SEER web site, April 2012, –2009 (Vintage 2009 Populations)
27.
Harris N, Swerdlow S, Jaffe E, Ott G, Nathwani B, de Jong D, Yoshino T, Spagnolo D: Follicular lymphoma. WHO classification of tumours of haematopoietic and lymphoid tissues. 2008, 220-226.
28.
Bierman PJ: Natural history of follicular grade 3 non-Hodgkin's lymphoma. Curr Opin Oncol. 2007, 19 (5): 433-437. 10.1097/CCO.0b013e3282c9ad78.CrossRefPubMed
29.
Fowler NH, Neelapu SS, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Orlowski RZ, Wang M: Lenalidomide and Rituximab for untreated indolent Lymphoma: final results of a phase II study. ASH Annual Meeting Abstracts. 2012, 120 (21): 901-
30.
Samaniego F, Hagemeister F, Mclaughlin P, Kwak LW, Romaguera J, Fanale MA, Neelapu SS, Fayad L, Orlowski RZ, Wang M: High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria. J Clin Oncol. suppl; abstr 8030
31.
Rawal S, Fowler N, Zhang M, Wang Z, Muzzafar T, Harun N, Baladandayuthapani V, Sharma R, Delgado D, Wallace M: Activation of T and NK Cells Following Lenalidomide Therapy in Patients with Follicular Lymphoma. ASH Annual Meeting Abstracts 2012. 2012, 120 (2): 2766-
32.
Dutia M, Deroock I, Reed-Pease C, Tuscano J: LENALIDOMIDE PLUS RITUXIMAB LEADS TO A HIGH RATE OF DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN'S LYMPHOMA. Ann Oncol. 2011, 22: 186-186.
33.
Leonard J, Jung S-H, Johnson JL, Bartlett N, Blum KA, Cheson BD: Alliance for clinical trials in oncology: CALGB 50401: a randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. SCO Meeting Abstracts. 2012, 30 (15):
34.
Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B: Oral Lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular, and transformed lymphoma: a phase II clinical trial. Leukemia. 2013, 10.1038/leu.2013.95. [Epub ahead of print]
35.
Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002, 346 (25): 1937-1947. 10.1056/NEJMoa012914.CrossRefPubMed
36.
Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000, 403 (6769): 503-511. 10.1038/35000501.CrossRefPubMed
37.
Friedberg JW: Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011, 2011: 498-505. 10.1182/asheducation-2011.1.498.CrossRefPubMed
38.
Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H: Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010, 28 (27): 4184-4190. 10.1200/JCO.2010.28.1618.PubMedCentralCrossRefPubMed
39.
Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR, Goy A, Witzig TE, Czuczman MS: Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 2011, 117 (22): 5058-5066. 10.1002/cncr.26135.CrossRefPubMed
40.
Zhang L-H, Kosek J, Wang M, Heise C, Schafer PH, Chopra R: Lenalidomide Efficacy in Activated B-Cell-Like Subtype Diffuse Large B-Cell Lymphoma Is Dependent Upon IRF4 and Cereblon Expression. ASH Annual Meeting Abstracts. 2012, 120 (21): 3287-
41.
Zinzani PL, Pellegrini C, Gandolfi L, Stefoni V, Quirini F, Derenzini E, Broccoli A, Argnani L, Pileri S, Baccarani M: Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk. 2011, 11 (6): 462-466. 10.1016/j.clml.2011.02.001.CrossRefPubMed
42.
Reddy NM, Simons RM, Caldwell ME, Chen H, Jagasia M, Morgan DS, Park SI, Greer JP, Richards KL: A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following R-CHOP chemotherapy for patients with high risk diffuse large B-cell lymphoma. ASH Annual Meeting Abstracts. 2012, 120 (21): 3668--
43.
Nowakowski GS, LaPlant B, Habermann TM, Rivera CE, Macon WR, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM: Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia. 2011, 25 (12): 1877-1881. 10.1038/leu.2011.165.CrossRefPubMed
44.
Nowakowski GS, LaPlant BR, Reeder C, Foran JM, Porrata LF, Macon WR, Johnston PB, Rivera CE, Habermann TM, Inwards DJ: Combination of Lenalidomide with R-CHOP (R2CHOP) is well-tolerated and effective as initial therapy for aggressive B-Cell lymphomas - a phase II study. ASH Annual Meeting Abstracts. 2012, 120 (21): 689-
45.
Bernstein SH, Burack WR: The incidence, natural history, biology, and treatment of transformed lymphomas. Hematology Am Soc Hematol Educ Program. 2009, 532-541.
46.
Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med. 1984, 311 (23): 1471-1475. 10.1056/NEJM198412063112303.CrossRefPubMed
47.
Yano T, Jaffe ES, Longo DL, Raffeld M: MYC rearrangements in histologically progressed follicular lymphomas. Blood. 1992, 80 (3): 758-767.PubMed
48.
Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, Sehn LH, Shenkier TN, Gascoyne RD, Connors JM: Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol. 2008, 26 (32): 5165-5169. 10.1200/JCO.2008.16.0283.CrossRefPubMed
49.
Czuczman MS, Vose JM, Witzig TE, Zinzani PL, Buckstein R, Polikoff J, Li J, Pietronigro D, Ervin-Haynes A, Reeder CB: The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. Br J Haematol. 2011, 154 (4): 477-481. 10.1111/j.1365-2141.2011.08781.x.CrossRefPubMed
50.
Verhelle D, Corral LG, Wong K, Mueller JH, Moutouh-de Parseval L, Jensen-Pergakes K, Schafer PH, Chen R, Glezer E, Ferguson GD: Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res. 2007, 67 (2): 746-755. 10.1158/0008-5472.CAN-06-2317.CrossRefPubMed
51.
Gaidarova S, Corral LG, Gleizer E, Young D, Brady H, Bennett B, Lopez-Girona A: Lenalidomide Enhances Anti-Tumor Effect of {gamma}{delta} T Cells against Mantle Cell Lymphoma. ASH Annual Meeting Abstracts. 2008, 112 (11): 2616-
52.
Zhang L-H, Schafer PH, Muller G, Stirling D, Bartlett B: Direct Inhibitory Effects of Lenalidomide on the Proliferation and VEGF Production of Non-Hodgkin Lymphoma Cells Are Associated with Increased SPARC Expression. ASH Annual Meeting Abstracts. 2008, 112 (11): 2612-
53.
Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, Brady HA, Gandhi AK, Schafer PH, Muller GW, Worland PJ, Chan KW, Verhelle D: Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 2009, 69 (18): 7347-7356. 10.1158/0008-5472.CAN-08-4898.CrossRefPubMed
54.
Gaidarova S, Corral LG, Glezer E, Schafer PH, Lopez-Girona A: reatment of MCL Cells with Combined Rituximab and Lenalidomide Enhances NK-Mediated Synapse Formation and Cell Killing. ASH Annual Meeting Abstracts. 2009, 114 (22): 1687-
55.
Gandhi AK, Kang J, Capone L, Shafarenko M, Schafer PH: Anti-Proliferative and Apoptotic Activity of Lenalidomide in Combination with Rituximab in Follicular Lymphoma: an in Vitro and Ex Vivo Analysis in Follicular Lymphoma Cells. ASH Annual Meeting Abstracts. 2009, 114 (22): 3723-
56.
Gaidarova S, Mendy D, Heise C, Aukerman SL, Daniel T, Chopra R, Lopez-Girona A: Lenalidomide Induces Capping of CD20 and Cytoskeleton Proteins to Enhance Rituximab Immune Recognition of Malignant B-Cells. ASH Annual Meeting Abstracts. 2010, 116 (21): 2845-
Metadata
Title
Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy
Authors
Madhav Desai
Kate J Newberry
Jorge Romaguera
Liang Zhang
Zhishuo Ou
Michael Wang
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2013
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-6-55

Other articles of this Issue 1/2013

Journal of Hematology & Oncology 1/2013 Go to the issue

Research

Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells

Review

MEK and the inhibitors: from bench to bedside

Research

Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study

Case report

Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral t-cell lymphoma

Short report

FISH+CD34+CD38- cells detected in newly diagnosed acute myeloid leukemia patients can predict the clinical outcome

Rapid communication

A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits